Phages of life – the path to pharma

British Journal of Pharmacology

Volumn 175, Issue 3, 2018, Pages 412-418

  Forde, Amanda ^b   Hill, Colin ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; SINGLE STRANDED DNA; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; BACTERIAL GENOME; BACTERIAL VIRULENCE; BACTERIOPHAGE; CAMPYLOBACTER; DNA EXTRACTION; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECIUM; GENE TRANSFER; HELICOBACTER PYLORI; LYSOGENIZATION; METAGENOMICS; MICROBIOME; MORPHOLOGY; NONHUMAN; PHAGE THERAPY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SPECIES DIVERSITY; STAPHYLOCOCCUS AUREUS; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; DRUG INDUSTRY; HUMAN; PHYSIOLOGY; PROCEDURES; TRENDS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIOPHAGES; DRUG INDUSTRY; HUMANS;

EID: 85039990070     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.14106     Document Type: Review

References (62)

1. Abedon S (2014). Bacteriophages as drugs: the pharmacology of phage therapy. In: Borysowski J, Międzybrodzki R, Górski A (eds). Phage Therapy: Current Research and Applications. Caister Academic Press: U.K.
2. Abedon S (2017a) Phage companies – companies.phage.org.
3. Abedon S (2017b). Information phage therapy research should report. Pharmaceuticals 10 pii: E43.
4. Bibby K (2014). Improved bacteriophage genome data is necessary for integrating viral and bacterial ecology. Microb Ecol 67: 242–244.
5. Bodier-Montagutelli E, Morello E, L'Hostis G, Guillon A, Dalloneau E, Respaud R et al. (2016). Inhaled phage therapy: a promising and challenging approach to treat bacterial respiratory infections. Expert Opin Drug Deliv 10: 1–14.
6. Bojanova DP, Bordenstein SR (2016). Faecal transplants: what is being transferred? PLoS Biol 14: e1002503.
7. Broecker F, Russo G, Klumpp J, Moelling K (2016). Stable core virome despite variable microbiome after faecal transfer. Gut Microbes 9: 1–7.
8. Brown TL, Petrovski S, Dyson ZA, Seviour R, Tucci J (2016). The formulation of bacteriophage in a semi solid preparation for control of Propionibacterium acnes growth. PLoS One 11: e0151184.
9. Bruder K, Malki K, Cooper A, Sible E, Shapiro JW, Watkins SC et al. (2016). Freshwater metaviromics and bacteriophages: a current assessment of the state of the art in relation to bioinformatic challenges. Evol Bioinform Online 12: 25–33.
10. Casadesús J (2016). Bacterial DNA methylation and methylomes. Adv Exp Med Biol 945: 35–61.
11. Chan BK, Abedon ST, Loc-Carrillo C (2013). Phage cocktails and the future of phage therapy. Future Microbiol 8: 769–783.
12. Chehoud C, Dryga A, Hwang Y, Nagy-Szakal D, Hollister EB, Luna RA et al. (2016). Transfer of viral communities between human individuals during faecal microbiota transplantation. MBio 7: e00322.
13. Cisek AA, Dąbrowska I, Gregorczyk KP, Wyżewski Z (2017). Phage therapy in bacterial infections treatment: one hundred years after the discovery of bacteriophages. Curr Microbiol 74: 277–283.
14. Clockie MRJ, Millard AD, Letarov AV, Heaphy S (2011). Phages in nature. Bacteriophage 1: 31–35.
15. Cooper CJ, Khan Mirzaei M, Nilsson AS (2016). Adapting drug approval pathways for bacteriophage-based therapeutics. Front Microbiol 7: 1209.
16. Curtright AJ, Abedon S (2011). Phage therapy: emergent property pharmacology. J Bioanal Biomed S6: 002.
17. D'Herelle F (1917). Sur un microbe invisible antagoniste des Bacillus dysenterique. CR Acad Sci Paris 165: 373–375.
18. Doss J, Culbertston K, Hahn D, Camacho J, Bareki N (2017). A review of phage therapy against bacterial pathogens of aquatic and terrestrial organisms. Virus 9: 50.
19. Dutilh BE, Cassman N, McNair K, Sanchez SE, Silva GG, Boling L et al. (2014). A highly abundant bacteriophage discovered in the unknown sequences of human faecal metagenomes. Nat Commun 5: 4498.
20. Enault F, Briet A, Bouteille L, Roux S, Sullivan MB, Petit MA (2017). Phages rarely encode antibiotic resistance genes: a cautionary tale for virome analyses. ISME J 11: 237–247.
21. Erez Z, Steinberger-Levy I, Shamir M, Doron S, Stokar-Avihail A, Peleg Y et al. (2017). Communication between viruses guides lyis-lysogeny decisions. Nature 541: 488–493.
22. Fancello L, Desnues C, Raoult D, Rolain JM (2011). Bacteriophages and diffusion of genes encoding antimicrobial resistance in cystic fibrosis sputum microbiota. J Antimicrob Chemoter 66: 2448–2454.
23. Fauconier A (2017). Regulating phage therapy. EMBO Rep 18: 198–200.
24. Górski A, Kniotek M, Perkowska-Ptasińska A, Mróz A, Przerwa A, Gorczyca W et al. (2006). Bacteriophages and transplantation tolerance. Transplant Proc 38: 331–333.
25. Górski A, Międzybrodzki R, Weber-Dąbrowska B, Fortuna W, Letkiewicz S, Rogóż P et al. (2016). Phage therapy: combating infections with potential for evolving from merely a treatment for complications to targeting diseases. Front Microbiol 7: 1515.
26. Gupta S, Allen-Vercoe E, Petrof EO (2016). Faecal microbiota transplantation: in perspective. Ther Adv Gastroenterol 9: 229–239.
27. Harper DR, Parracho HMRT, Walker J, Sharp R, Hughes G, Werthén M et al. (2014). Bacteriophages and biofilms. Antibiotics 3: 270–284.
28. Hayes S, Mahony J, Nauta A, van Sinderen D (2017). Metagenomic approaches to assess bacteriophages in various environmental niches. Virus 9 pii: E127.
29. Jun SY, Jang IJ, Yoon S, Jang K, Yu KS, Cho JY et al. (2017). Pharmacokinetics and tolerance of the phage endolysin-based candidate drug SAL200 after a single intravenous administration among healthy volunteers. Antimicrob Agents Chemother 61. pii: e02629-16): e02629–e02616.
30. Keen EC, Bliskovsky VV, Malagon F, Baker JD, Prince JS, Klaus JS et al. (2017). Novel ‘superspreader’ bacteriophages promote horizontal gene transfer by transformation. MBio 8: e02115–e02116.
31. LaFee S, Buschman H (2017). Novel therapy saves patient with multi-drug resistant bacterial infection. Available at: https://health.ucsd.edu/news/releases/Pages/2017-04-25-novel-phage-therapy-saves-patient-with-multidrug-resistant-bacterial-infection.aspx (accessed 25/04/2017).
32. Lekunberri I, Subirats J, Borrego CM, Balcázar JL (2016). Exploring the contribution of bacteriophages to antibiotic resistance. Environ Pollut 220: 981–984.
33. Loc-Carillo C, Abedon ST (2011). Pros and cons of phage therapy. Bacteriophage 1: 111–114.
34. Łusiak-Szelachowska M, Żaczek M, Weber-Dąbrowska B, Międzybrodzki R, Kłak M, Fortuna W (2014). Phage neutralization by sera of patients receiving phage therapy. Viral Immunol 27: 295–304.
35. Ly M, Jones MB, Abeles SR, Santiago-Rodriguez TM, Gao J, Chan IC et al. (2016). Transmission of viruses via our microbiomes. Microbiome 4: 64.
36. Malik DJ, Sokolov IJ, Vinner GV, Mancuso F, Cinquerrui S, Vladisavljevic GT et al. (2017). Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Adv Colloid Interface Sci 249: 100–133. https://doi.org/10.1016/j.cis.2017.05.014.
37. Manrique P, Bolduc B, Walk ST, van der Oost J, de Vos WM, Young MJ (2016). Healthy human gut phageome. Proc Natl Acad Sci U S A 113: 10400–10405.
38. Mills S, Shanahan F, Stanton C, Hill C, Coffey A, Ross RP (2013). Movers and shakers: influence of bacteriophages in shaping the mammalian gut microbiota. Gut Microbes 4: 4–16.
39. Mirzaei MK, Maurice CF (2017). Ménage à trois in the human gut: interactions between host, bacteria and phages. Nat Rev Microbiol 15: 397–408. https://doi.org/10.1038/nrmicro.2017.30.
40. Modi SR, Lee HH, Spina CS, Collins JJ (2013). Antibiotic treatment expands the resistance reservoir and ecological network of the phage metagenome. Nature 499: 219–222.
41. Murphy J, Mahony J, Ainsworth S, Nauta A, van Sinderen D (2013). Bacteriophage orphan DNA methyltransferases: insights from their bacterial origin, function, and occurrence. Appl Environ Microbiol 79: 7547–7555.
42. Navarro F, Muniesa M (2017). Phages in the human body. Front Microbiol 8: 566.
43. Norman JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC et al. (2015). Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell 160: 447–460.
44. O'Flaherty S, Ross RP, Coffey A (2009). Bacteriophage and their lysins for elimination of infectious bacteria. FEMS Microbiol Rev 33: 801–819.
45. Oliveira H, Silankorva S, Merabishvili M, Kluskens LD, Azeredo J (2015). Unexploited opportunities for phage therapy. Front Pharmacol 6: 180.
46. Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bharti R, Grasis JA et al. (2017). Efficacy of sterile faecal filtrate transfer for treating patients with Clostridium difficile infection. Gastroenterology 152: 799–811.
47. Palfrene E, Willebrand E, Cavaleiro Sanches A, Sebris Z, Cavaleri M (2016). (2016). Bacteriophage therapy: a regulatory perspective. J Antimicrob Chemother 71: 2071–2074.
48. Pei R, Lamas-Samanamud GR (2014). Inhibition of biofilm formation by T7 bacteriophages producing quorum-quenching enzymes. Appl Environ Microbiol 80: 5340–5348.
49. Reyes A, Haynes M, Hanson N, Angly FE, Heath AC, Rohwer F et al. (2010). Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature 466: 334–348.
50. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A (2009). Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 18: 240–243.
51. Roach DR, Debarbieux L (2017). Phage therapy: awakening a sleeping giant. Emerg Top Life Sci 1: 93–103.
52. Roux S, Krupovic M, Debroas D, Forterre P, Enault F (2013). Assessment of viral community functional potential from viral metagenomes may be hampered by contamination with cellular sequences. Open Biol 3: 130160.
53. Sarker SA, Brüssow H (2016). From bench to bed and back again: phage therapy of childhood Escherichia coli diarrhoea. Ann N Y Acad Sci 1372: 42–52.
54. Sekirov I, Russell SL, Antunes LC, Finlay BB (2010). Gut microbiota in health and disease. Physiol Rev 90: 859–904.
55. Sulakvelidze A, Alavidze Z, Morris JG (2001). Bacteriophage therapy. Antimicrob Agents Chemother 45: 649–659.
56. Tacconelli E, Magrini N (2017). Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Available at: http://www.who.int/entity/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1 (accessed 27/02/2017).
57. Touchon M, Moura de Sousa JA, Rocha EP (2017). Embracing the enemy: the diversification of microbial gene repertoires by phage-mediated horizontal gene transfer. Curr Opin Microbiol 38: 66–73.
58. Twort FW (1915). An investigation on the nature of ultra-microcopic viruses. Lancet 186: 1241–1243.
59. Wahida A, Ritter K, Horz HP (2016). The Janus-Face of bacteriophages across human body habitats. PLoS Pathog 12: e1005634.
60. Wright A, Hawkins CH, Änggård EE, Harper DR (2009). A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 34: 349–357.
61. Zelasko S, Gorski A, Dabrowska K (2017). Delivering phage therapy per os: benefits and barriers. Expert Rev Anti Infect Ther 15: 167–179.
62. Zuo T, Wong SH, Lam K, Lui R, Cheung K, Tang W et al. (2017). Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome. Gut pii: gutjnl-2017-313952 : gutjnl-2017-313952.